DK3976581T3 - Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine - Google Patents

Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine Download PDF

Info

Publication number
DK3976581T3
DK3976581T3 DK20725728.8T DK20725728T DK3976581T3 DK 3976581 T3 DK3976581 T3 DK 3976581T3 DK 20725728 T DK20725728 T DK 20725728T DK 3976581 T3 DK3976581 T3 DK 3976581T3
Authority
DK
Denmark
Prior art keywords
sulfonylphenoxy
fluoro
methane
propyl
amine
Prior art date
Application number
DK20725728.8T
Other languages
English (en)
Inventor
Inese Reine
Clas Sonesson
Ross Nicholas Waters
Joakim Mihkel Tedroff
Original Assignee
Irl 790 Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irl 790 Ab filed Critical Irl 790 Ab
Application granted granted Critical
Publication of DK3976581T3 publication Critical patent/DK3976581T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK20725728.8T 2019-05-24 2020-05-20 Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine DK3976581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19176514 2019-05-24
EP20166361 2020-03-27
PCT/EP2020/064046 WO2020239568A1 (en) 2019-05-24 2020-05-20 Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof

Publications (1)

Publication Number Publication Date
DK3976581T3 true DK3976581T3 (da) 2024-01-22

Family

ID=70682855

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20725728.8T DK3976581T3 (da) 2019-05-24 2020-05-20 Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine

Country Status (21)

Country Link
US (2) US12275694B2 (da)
EP (2) EP4292653B1 (da)
JP (1) JP7623958B2 (da)
KR (1) KR102892833B1 (da)
CN (1) CN113853369B (da)
AU (1) AU2020286003B2 (da)
BR (1) BR112021023563A2 (da)
CA (1) CA3140805A1 (da)
CL (1) CL2021003115A1 (da)
CO (1) CO2021016556A2 (da)
DK (1) DK3976581T3 (da)
ES (1) ES2970361T3 (da)
FI (1) FI3976581T3 (da)
IL (1) IL288271B2 (da)
JO (1) JOP20210312A1 (da)
MX (1) MX2021014271A (da)
PH (1) PH12021552844A1 (da)
PL (1) PL3976581T3 (da)
PT (1) PT3976581T (da)
SG (1) SG11202112165QA (da)
WO (1) WO2020239568A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3976581T3 (da) 2019-05-24 2024-01-22 Irl 790 Ab Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine
WO2022101227A1 (en) * 2020-11-10 2022-05-19 Integrative Research Laboratories Sweden Ab [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias
US20260053759A1 (en) * 2022-08-24 2026-02-26 Alkem Laboratories Limited Mesdopetam compositions
WO2024062344A1 (en) 2022-09-21 2024-03-28 Assia Chemical Industries Ltd. Solid state forms of mesdopetam and salts therof
GB202312055D0 (en) * 2023-08-07 2023-09-20 Ipsen Biopharm Ltd Pharmaceutical compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123821A (en) 1975-04-18 1976-10-28 Nippon Kayaku Co Ltd An algicide and protective agent
US4128574A (en) * 1976-10-04 1978-12-05 General Electric Company Method for making organic polycarboxylic acids
GB8823405D0 (en) 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
PT707007E (pt) 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
JP2006193494A (ja) 2005-01-17 2006-07-27 Dainippon Ink & Chem Inc 4級アンモニウム系化合物を有効成分とする心臓疾患治療剤
EP1899326A4 (en) 2005-06-23 2009-12-16 Albireo Ab NOVEL AZETIDINE DERIVATIVES USEFUL AS ANTAGONISTS OF NEUROKININ RECEPTORS IN THE TREATMENT OF GASTROINTESTINAL DISEASES
JP5210637B2 (ja) 2005-11-29 2013-06-12 キッセイ薬品工業株式会社 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2007072041A1 (en) 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds
US20090221607A1 (en) * 2006-02-15 2009-09-03 M's Science Corporation Piperazine Derivatives
EP2155668A2 (en) * 2007-06-08 2010-02-24 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-ý4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
JP2011519839A (ja) 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
DK2271638T3 (da) 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
WO2009133107A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CA2832874C (en) 2011-04-19 2019-06-11 Integrative Research Laboratories Sweden Ab Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
CA2970799A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
CA3228796A1 (en) * 2016-02-08 2017-08-17 Merck Patent Gmbh Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
JP7126522B2 (ja) * 2017-05-19 2022-08-26 インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー (+)-3-(2,3-ジフルオロフェニル)-3-メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用
SI3649124T1 (sl) * 2017-08-07 2021-09-30 Suven Life Sciences Limited Fluoropiperidinske spojine kot čisti 5-HT6 receptor antagonisti
WO2020110128A1 (en) 2018-11-29 2020-06-04 Prilenia Neurotherapeutics Ltd. Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
DK3976581T3 (da) 2019-05-24 2024-01-22 Irl 790 Ab Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine

Also Published As

Publication number Publication date
US20250243155A1 (en) 2025-07-31
MX2021014271A (es) 2022-01-06
CN113853369A (zh) 2021-12-28
PH12021552844A1 (en) 2022-10-17
JOP20210312A1 (ar) 2023-01-30
EP4292653A2 (en) 2023-12-20
CN113853369B (zh) 2025-08-22
IL288271B2 (en) 2025-02-01
EP3976581B1 (en) 2023-11-22
WO2020239568A1 (en) 2020-12-03
CL2021003115A1 (es) 2022-09-30
US12275694B2 (en) 2025-04-15
SG11202112165QA (en) 2021-12-30
US20240343687A2 (en) 2024-10-17
PL3976581T3 (pl) 2024-07-01
KR20220011638A (ko) 2022-01-28
AU2020286003B2 (en) 2025-04-24
CO2021016556A2 (es) 2022-01-17
IL288271A (en) 2022-01-01
EP4292653A3 (en) 2024-04-24
CA3140805A1 (en) 2020-12-03
EP3976581A1 (en) 2022-04-06
FI3976581T3 (fi) 2024-01-31
BR112021023563A2 (pt) 2022-01-04
JP7623958B2 (ja) 2025-01-29
US20220267262A1 (en) 2022-08-25
AU2020286003A1 (en) 2021-12-02
ES2970361T3 (es) 2024-05-28
JP2022533433A (ja) 2022-07-22
EP4292653B1 (en) 2026-03-18
PT3976581T (pt) 2024-02-08
IL288271B1 (en) 2024-10-01
KR102892833B1 (ko) 2025-12-02

Similar Documents

Publication Publication Date Title
PL3976581T3 (pl) Sole kwasu winowego [2-(3-fluoro-5-metanosulfonylofenoksy)etylo](propylo)aminy
EP4083038A4 (en) PYRIDAZINYL THIAZOLECARBOXAMIDE COMPOUND
DK4061812T3 (da) Forbindelser som er nyttige som inhibitorer af heliosprotein
CY2024024I2 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4- μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
HUE069570T2 (hu) Nitril-tartalmú vegyületek gyógyszerként történõ alkalmazásra
DK3743411T3 (da) Herbicidt virksomt 3-phenylisoxazolin-5-carboxamider af cyclopentenylcarbonsyrederivater
IL288997A (en) Salt forms of bempedoic acid and methods for using the same
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
IL289439A (en) Heterocyclic compounds as bet inhibitors
EP3402799A4 (en) Heterocyclic compounds as RSV inhibitors
IL286218A (en) Solid state forms of ripretinib
DK4055021T3 (da) Heterocykliske rip1-inhiberende forbindelser
DK3658552T3 (da) Fremgangsmåde til fremstilling af n-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamid ved reaktion af den tilsvarende amin med et 3-halogen-propionylchlorid
LT3993807T (lt) Vaistą apimančios vandeninės kompozicijos ph stabilizavimo būdas
EP3414256A4 (en) AMINO SALT OF OBETICHOLIC ACID
EA201401084A1 (ru) Соли 5-[(1r)-2({2-[4-(2,2-дифтор-2-фенилэтокси)фенил]этил}амино)-1-гидроксиэтил]-8-гидроксихинолин-2(1н)-она
EP4003323A4 (en) STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES
IL285721A (en) Methods of making high enantioselective secondary alcohols
IL238011A0 (en) Derivatives of n-(2-(cyclic amine)ethyl)benzamide as p2x7 inhibitors
HUE063674T2 (hu) Eljárás N-(amino-imino-metil)-2-aminoetánsav (III) metastabil kristálymódosulatának elõállítására
DK2819998T3 (da) Krystallinske former af 1-(3-tert-butyl-1-P-tolyl-1H-pyrazol-5-yl)-3-(5-fluor-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)ureahydrochlorid
EP3919485A4 (en) CRYSTALS OF QUINOLINE DERIVATIVES
PL4082616T3 (pl) Pochodna amidowa kwasu alifatycznego
IL290181A (en) Process for the preparation of fluensulfone
HUE066959T2 (hu) Eljárás anilin tisztítására